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Introduction 
 
In D. melanogaster and C. elegans reduced expression of the non-
electrogenic dicarboxylate and citrate transporter Indy (Acronym for 
I´m Not Dead Yet) promotes longevity in a manner akin to caloric 
restriction, one of the most reliable interventions to prolong life span 
over a wide range of species [ ,2]. In mammals, SLC 3A5 encodes 
the Na+-coupled citrate transporter NaCT (we will use the alternative 
name mINDY throughout the review), which shares the highest 
sequence and functional similarity with D. melanogaster Indy.  
mINDY-/- knockout mice are protected from diet induced obesity 
and insulin resistance that go along with excess caloric intake and 
aging [3]. The effect is mediated by a profound action of mINDY on 
mitochondrial metabolism in mice. Therefore, mINDY might serve as 
a therapeutic target for the treatment of obesity and type-2 diabetes. 
The purpose of this review is to summarize the role of mINDY in 
mammalian glucose and energy metabolism and describe the most 
recent advances on structure, expression, function and regulation of 
the protein.   
 
The SLC 3A family – an overview  
 
The SLC 3A family of Na+-coupled di- and tri-
carboxylate/sulfate transporters comprises five genes, namely 
SLC 3A -5, encoding multi-spanning transporters with 8- 3 
transmembrane -helices flanked by an intracellular N-terminus and 
an extracellular C-terminus, containing putative consensus 
glycosylation sites [4]. Orthologs of all five genes are found in 
prokaryotes  and  eukaryotes. All  SLC 3A  family  members  contain  
 
 
 
 
 
 
 
 
 
 
numerous predicted consensus phosphorylation and N-
myristyoylation sites for which the functional significance is unknown 
so far. Moreover, a highly conserved consensus sequence motif, the 
“sodium:sulfate symporter family signature’’, is found in each of the 
five family members [5]. 
The mammalian SLC 3A Na+-coupled anion cotransporters are 
located in the plasma membrane of epithelial cells with ubiquitous 
expression, but mainly in liver, kidney, small intestine, placenta and 
cells of the central nervous system. They all play a variety of different 
physiological and pathophysiological roles in the different organs. 
SLC 3A transporters mediate the Na+-coupled anion substrate 
movement across the plasma membrane of cells and are electrogenic 
with a general Na+:substrate ratio of 3: .  
SLC 3A family members are divided in two functional groups: 
the Na+-sulfate cotransporters (NaS) mainly transporting sulfate, 
selenate and thiosulfate and the Na+- di- and tri-carboxylate 
cotransporters (NaDC) carrying Krebs-cycle intermediates such as 
succinate, citrate and -ketoglutarate. While the SLC 3A  and 
SLC 3A4 genes belong to the NaS, the SLC 3A2, SLC 3A3 and 
SLC 3A5 genes represent the NaDC group. 
SLC 3A  (also NaS  or NaSi- ) is localized to the apical brush 
border membrane of the renal proximal tubules and intestinal 
epithelial cells [6-9]. SLC 3A  functions as an electrogenic pH-
sensitive high affinity Na+-dependent SO-24 transporter with substrate 
preferences for the anions sulfate, thiosulfate, selenate and the cation 
Na+ [ 0, ]. The human SLC 3A  transporter can be inhibited by 
molybdate, selenate, tungstate, selenate, succinate and citrate [6]. 
SLC 3A  deficient mice revealed numerous pathophysiological 
features, such as hyposulfatemia, hypersulfaturia, reduced body 
weight, postnatal growth and fertility, reduced circulating steroid 
levels, increased urinary glucocorticoid excretion and altered lipid and 
cholesterol metabolism within the liver [ 2- 9]. The loss of 
SLC 3A  clearly shows its importance in maintaining sulfate 
homeostasis. 
SLC 3A2 is localized in epithelia with high metabolic needs 
specifically on the apical membrane of renal proximal tubular and 
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small intestine cells where it reabsorbs intermediates of the 
tricarboxylic acid cycle like succinate, -ketoglutarate and citrate. The 
activity and cell surface expression of SLC 3A2 is dependent on its 
regulation by PKC-dependent, direct-phosphorylation independent 
pathways including the serum and glucocorticoid inducible kinases 
SGK  and 3, PKB kinase and the NHE regulating factor 2 
(NHERF2) [20,2 ]. By taking up tricarboxylic acid (TCA) cycle 
intermediates into cells across the apical membrane, SLC 3A2 plays 
an important role in oxidative metabolism. SLC 3A2-/- mice are 
characterized by increased urinary excretion of diverse dicarboxylates 
[22].  
The main function of SLC 3A2 is renal handling of citrate and 
therefore important in the formation of kidney stones and 
nephrolithiasis [20,23]. Since the SGK  signaling pathway, 
contributing to the regulation of renal function and arterial blood 
pressure, activates SLC 3A2, the protein may also be important in 
the regulation of blood pressure, in addition to its role in water re-
absorption [24]. 
SLC 3A3 is conserved over a wide range of species and has been 
detected in zebrafish, xenophus frog, mouse and human [25]. 
SLC 3A3 is expressed in liver, brain, kidney, placenta, pancreas, eye 
and optic nerve and is located on the apical membrane of placenta and 
synaptosomes and on the basolateral membrane of hepatocytes and 
renal proximal tubular cells. Slc 3a3 is found mainly in astrocytes and 
at lower degree in neurons within the central nervous system [26-3 ]. 
SLC 3A3 shows a substrate preference for succinate, -ketoglutarate 
and citrate and is inhibited by TCA cycle intermediates, such as  
fumarate, oxaloacetate or malate [32]. So far, no SLC 3A3 deficient 
mouse model has been described, but it was reported that renal 
mRNA and protein expression levels increase with age in humans and 
rats [33]. Moreover, SLC 3A3 activity and plasma membrane 
expression are regulated via PKC-dependent and -independent 
mechanisms [34,35]. Moreover, SLC 3A3 seems to be involved in 
the regulation of cellular senescence by a mechanism including the 
NAD-(+)-dependent histone deacetylase sirtuin-  (SIRT ) [36]. 
SLC 3A3 expression has been shown to be regulated by the 
transcription factor paired-like homeodomain transcription factor 2 
(PITX2) in ocular cells and was suggested to be important in the 
inborn metabolic disease Axenfeld-Rieger syndrome type  (ARS ), 
an autosomal dominant disorder of morphogenesis. ARS  is caused 
by mutations in PITX2 leading to abnormal eye anterior segment 
development which could result in glaucomatous blindness [37]. 
Moreover SLC 3A3 was identified by genomic analysis to be 
associated with hypertension and type-2 diabetes [38-40]. 
SLC 3A4 is mainly expressed in placenta and testis and at a lower 
extent in brain, heart, thymus, liver and tonsils [4 ,42]. The Na+-
dependent transport of sulfate can be inhibited by substrates with 
similar structures like molybdate and selenate most likely by substrate 
competition [42]. So far no SLC 3A4 null mouse model has been 
described, and remains to be determined whether or not SLC 3A4 is 
involved in any human disorder (for an overview see table ). 
 
SLC 3A5 – structure, expression and function   
 
Cytosolic citrate is known as the prime carbon source for the 
synthesis of fatty acids, triacylglycerols, cholersterols and low-density 
lipoproteins. Moreover citrate leads to the activation of fatty acid 
synthesis and affects glycolysis and ß-oxidation [43-45]. An overview 
is provided in Figure . Main organs for fatty acid synthesis are the 
liver and white adipose tissue. Fatty acid synthesis has been shown to 
directly correlate with cytosolic citrate concentrations, partially 
depending on the direct import across the plasma membrane by 
mINDY [46,47]. 
Initially, the significance of Indy in lifespan and metabolic 
regulation has been described in D. melanogaster, where it encodes an 
electroneutral tricarboxylate carrier, mainly expressed in organs 
involved in energy homeostasis and preferentially transporting citrate 
across the plasma membrane in flies [2,46,48-54]. Long lived flies 
with reduced expression of Indy showed a reduction in whole body 
fat stores and less expression of insulin like proteins, comparable to 
levels in calorically restricted wildtype flies [55]. 
The mammalian Indy homolog, mINDY, or SLC 3A5, was 
identified as the latest member of the SLC 3 gene family and consists 
of  transmembrane domains [46]. The bacterial INDY homologue 
protein binds one molecule of citrate and one molecule of sodium. 
Here, the binding sides exist of conserved amino acid proteins, serving 
as the structural basis of the transporter specificity, which is conserved 
over a wide range of species [48]. The Na+:citrate stoichiometry for 
mINDY is 4: , which is in contrast to the other SLC 3 family 
members. The SLC 3A5 gene encodes the Na+-coupled citrate 
transporter mINDY (NaCT) and shares the highest sequence and 
functional similarity with D. melanogaster Indy. In humans, the 
INDY gene is located on chromosome 7p 3 with a size of 
approximately 30kb consisting of 2 exons [46]. A splice variant 
lacking 43 N-terminal residues has been reported by Pajor and 
colleagues, the function and tissue distribution are still unknown [56]. 
Mammalian tissue distribution studies have localized predominant 
INDY expression within the liver, but also in testis and 
brain[3,46,5 ]. Within neuronal tissues, mINDY shows an exclusive 
expression pattern in neurons but not in astrocytes [27] [29].  
mINDY has a vast substrate specificity for the tricarboxylate 
citrate and exhibits the inward electrogenic Na+-coupled substrate 
cotransport. It has been reported, that mINDY mediated citrate 
transport is pH-sensitive and maximal activity is exhibited at pH 7.0-
7.5, whereas the transporter is inhibited in acidic and alkaline pH 
[52]. 
The transporter shows lower affinities to other Krebs-cycle 
intermediates such as succinate, malate or fumarate [46,5 ,52]. 
mINDY is less selective to other organic anions since it is not 
mediating  the uptake of glutarate derivates into neurons [57]. 
Moreover, mINDY is Li+-sensitive, varying largely between species. 
While human mINDY is stimulated by Li+, it is inhibited or 
unaffected in other species [47,58].  
Several lines of evidence suggest that transcriptional regulation of 
mINDY is mediated by the nutritional state, suggesting metabolic 
factors being involved in the regulation. For example, Indy expression 
is reduced by caloric restriction in flies [55], whereas caloric 
restriction increases INDY expression in bicyclus anynana butterflies 
[59]. In mice, starvation over 36 hours reduces mINDY expression in 
the liver [3]. In contrast, gavaging large amounts of olive oil induced 
INDY expression strongly in the liver in rats, as identified by 
microarray assays [60].  Etcheverry and colleagues could show that the 
regulation of mINDY is mediated by epigenetic mechanisms. 
Profiling of whole genome integrative analysis of methylation and 
gene expression in glioblastoma patients possessed several genes, 
showing an inverse correlation between promoter methylation and 
expression level in glioblastomas. Moreover, INDY was down-
regulated with hypermethylation of its promoter [6 ].  
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Recently, we have demonstrated that mINDY expression and 
citrate uptake was induced by physiological concentrations of the 
hormone glucagon via a cAMP and cAMP-responsive-element-
binding-protein (CREB)- dependent mechanism. The promoter 
sequence of mINDY was identified including a CREB binding site 
within this fragment, identifying mINDY as a CREB-dependent 
glucagon target gene, which is induced in the short term fasting status 
and type-2 diabetes [62]. 
Since mINDY is predominately expressed in the liver, a 
metabolically highly active organ, it may play a role in various 
metabolic processes in which citrate has an important function such as 
mitochondrial energy production (TCA cycle), fatty acid synthesis, 
cholesterol synthesis, glycolysis and gluconeogenesis [58]. 
Citrate is imported from the circulation across the plasma 
membrane into the liver by an electrogenic citrate-sodium co-
transport via mINDY (NaCT) and other family members of the 
SLC 3 transporter family. Citrate generated within the mitochondria 
by each turn of the TCA cycle also enters the cytoplasm when 
intracellular energy stores are abundant. Cytoplasmic citrate is 
converted to acetyl-CoA by ATP-citrate lyase (ACLY). The 
conversion of acetyl-CoA to malonyl-CoA by acetyl-CoA carboxylase 
(ACC) is the first step in fatty acid synthesis. ACC gets allosterically 
activated by citrate.  The product from this reaction, malonyl-CoA, 
serves as the donor of C2-acetly groups in each turn of the fatty acid 
synthesis reaction cycle. The ACLY reaction also yields oxaloacetate, 
which can be decarboxylated and phosphorylated to form 
phosphoenolpyruvate (PEP), through phosphoenolpyruvate 
carboxykinase. A (PEPCK), opening into gluconeogenesis. Moreover, 
acetyl-CoA can be routed into cholesterol synthesis via several 
enzymes including 3-hydroxy-3-methylglutaryl-coenzym-A-reductase 
(HMG-CoA-reductase).Green lines indicate activating and red lines 
inhibitory connections. ATP – Adenosine triphosphate, CTP – 
citrate transport protein, F- ,6-BP – Froctose- ,6-bisphosphatase, 
PFK – Phosphofructokinase, TCA – tricarboxylic acid. 
 
Regulation of citrate homeostasis by SLC 3 members 
 
Serum citrate concentration is relatively constant, ranging from 
50-200 μM [62,63]. Citrate absorption from nutritional sources in 
the small intestine seems to be mediated mainly via NaDC  and 
NaDC3 [64,65]. By this mechanism, more than 90% of an oral 
citrate load can be absorbed and hypocitraturia can be ameliorated 
[64,66]. At physiological pH, most of serum citrate circulates in the 
form of triply charged citrate bound  to divalent ions, such as calcium 
and magnesium, and is filtered freely at the glomerulus; reabsorption 
takes place predominantly in the proximal tubule via NaDC  [65]. 
Moreover, citrate is also taken up into the kidney by removal from 
postglomerular blood. Interestingly, similar to our findings in the 
liver, citrate is also oxidized in the TCA cycle in the kidney and it has 
been reported to be metabolized to glucose in gluconeogenesis in the 
kidney [3,62]. By these mechanisms, citrate contributes to meet the 
energy needs of the kidney [67-70]. In addition to kidney, citrate is 
also taken up by the liver via mINDY and NaDC3. There, it can be 
oxidized or it can be used for the synthesis of fatty acids and glucose 
(figure ) [62].  
INDY and Metabolism 
3 
Volume No: 6, Issue: 7, e201303020 Computational and Structural Biotechnology Journal | www.csbj.org 
 
 
 
 
 
Circulating citrate is released from muscle, skin and bone. Citrate 
concentrations in bone exceed that of most other tissues and accounts 
for 70% of total body citrate content[7 ]. Citrate can also be taken 
up into the bone, being deposited in the mineral fraction and mINDY 
has recently identified in bone matrix, probably contributing to the 
function [7 ,72]. Skeletal muscle, with its high capacity for oxidative 
substrate utilization is probably a major source of citrate release to the 
plasma pool. The isolated rat hindquarter releases considerable 
amounts of citrate [73]. Arterio-femoral plasma citrate difference in 
the working man is largely negative, and the working muscle can be 
considered as one of the major sources of plasma citrate during 
exercise [74]. Moreover, the human heart has also been shown to 
release citrate, and is has been postulated that similarly to liver and 
kidney, this function may contribute the regulation of myocardial 
lipid and glucose metabolism [75].   
The physiological significance of the regulation of plasma citrate 
homeostasis is largely unknown. The plasma halflife of citrate in the 
dog is about 20 minutes, and citrate turnover rates have been 
estimated to equal 250μmol/h/L in man, with a tissue to plasma 
gradient of 3-4 to [70]. Externally administered citrate is oxidized 
to a major extend and it might, hence, contribute to furnish cellular 
energy needs. Citrate concentrations undergo significant circadian 
rhythmicity peaking in the postprandial phase, a pattern that seems to 
be disturbed in type  diabetics [76,77]. In these patients, insulin 
decreases circulating citrate levels. Prolonged fasting also reduces 
citrate levels in men. Moreover, we have found that glucagon increases 
the expression of SLC 3A5 via the transcription factor CREB in rats, 
and by this mechanism, increases the uptake of citrate into the liver in 
early fasting [62]. 
 
Metabolic regulation through SLC 3A5  
 
INDY might be involved in metabolic regulation since it 
transports intermediates of the TCA cycle and reducing the 
expression of Indy promotes longevity in a manner akin to caloric 
restriction in flies [55,78]. Caloric restriction was shown to prolong 
life span, or at least health span, in many species including primates 
[79-83]. 
 Deletion of the Indy homolog ceNAC-2 in C.elegans leads to 
prolonged lifespan with a reduction in whole body fat stores 
[2,53,55,84]. In D. melanogaster, Indy encodes a non-electrogenic, 
dicarboxylate and citrate transporter mainly expressed in organs of 
intermediary metabolism, i.e. the fat body, midgut and oenocyte [2]. 
The mammalian protein mINDY shares highest sequence and 
functional similarity with the fly Indy gene [46].  
To examine the metabolic effects mINDY might have in 
mammals, we created a whole body knockout mouse model  
(mINDY-/- mouse). mINDY-/- mice displayed a reduction in the  
uptake of citrate from the circulation into the liver, but not kidney 
and adipose tissue, paralleled by elevated circulating citrate levels 
[3,85]. mINDY-/- mice did not gain as much weight as control mice, a 
phenotype getting more pronounced with age. The observation was 
accompanied by a somewhat unexpected increase in oxygen 
consumption, carbon dioxide generation and resting energy 
expenditure. In this vein, hepatic mitochondrial density and gene 
expression of the peroxisome proliferator-activated receptor-gamma 
coactivator  alpha (PGC -α) were increased in mINDY-/- mice. 
Hepatic microarray studies revealed important similarities between 
mINDY-/- mice and calorically restricted mice, sharing ~ 80 % of 
similar transcriptional changes, including increased expression of 
electron transport chain components.  
Consequently, on a high fat diet, mINDY-/- mice showed less 
body weight gain compared to control mice. Moreover, fat mass was 
significantly reduced by almost 50% and relative lean mass was 
increased as measured by nuclear magnet resonance. Hepatic 
triglyceride content was reduced upon mINDY deficiency 
concomitant with reduced liver lipid deposits. Moreover, the hepatic 
lipid oxidation marker, beta-hydroxybutyrate, was increased in high 
caloric fed mice by 62%. Measurements of lipid oxidation in primary 
hepatocytes isolated from high caloric diet fed mINDY-/- mice 
revealed a reduced incorporation of citrate into fatty acids and sterols. 
Together, these data indicate that high fat diet fed mINDY knockout 
mice have elevated lipid oxidation and reduced lipid synthesis rates 
compared to controls [3].  
AMP-activated protein kinase (AMPK) is activated by increased 
intracellular adenosine monophosphate (AMP) stores and inhibited 
when adenosine triphosphate (ATP) reservoirs are high. Hence, 
AMPK is able to serve as a cellular energy sensor, coordinating insulin 
sensitivity, lipid-oxidation and -synthesis and mitochondrial 
biogenesis via the transcriptional co-activator PGC -α [86,87] In the 
mINDY-/- mice, ATP stores were reduced and AMPK 
phosphorylation was increased, suggesting an increased activation of 
AMPK through reduced intracellular biochemical energy stores [3]. 
Feeding mice a high fat diet serves as a well-known model to 
study obesity related impairment in glucose metabolism [88-92]. For 
this purpose, mINDY-/- mice were fed a high fat diet, and the impact 
of mINDY deletion on glucose metabolism was studied in vivo, by 
intraperitoneal glucose tolerance tests (ipGTT) first. Basal plasma 
glucose and insulin concentrations were decreased in mINDY-/- mice 
compared to control mice. Then, the gold standard to study insulin 
sensitivity, the hyperinsulinemic euglycemic clamp, demonstrated 
improved insulin sensitivity with reduced basal and clamp endogenous 
hepatic glucose production upon mINDY deletion. Additionally, 
peripheral glucose uptake by the gastrocnemius muscle was increased 
in INDY deletion mice. This protection from fat-induced muscle 
insulin resistance was accompanied by reduced content of skeletal 
muscle DAGs as major mediators of insulin resistance [93-97]. 
Hepatic insulin resistance is strongly associated with hepatic lipid 
accumulation [98]. A simple unifying hypothesis that has been 
proposed to explain these observations is that insulin resistance 
Figure 1. Schematic representation of metabolic pathways affected by 
intracellular citrate molecules. 
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develops when there is an imbalance between supply and utilization of 
intracellular lipid leading to net accumulation of intracellular 
diacylglycerol (DAG hypothesis) [93,98,99]. Increased DAG content 
in turn results in activation of novel protein kinase C’s (PKC’s) and 
subsequent impairment in insulin signaling. With high-fat feeding, 
this condition is achieved due to the continued, high supply of dietary 
fat, which exceeds the capacity of hepatocytes to oxidize the fatty 
acids, store the fatty acids as neutral lipid or export fatty acids in 
VLDL (very low-density lipoprotein) particles. In contrast, with 
aging, declines in mitochondrial function may contribute to net 
accumulation of intracellular DAGs [99]. Consistent with this 
hypothesis, mINDY-/- mice showed reduced hepatic DAG 
concentrations, decreased membrane PKCε content, and protection 
from hepatic insulin resistance associated with high-fat feeding and 
aging. Confirmation of this key interaction between DAG, activation 
of PKCε, and insulin resistance has been demonstrated in numerous 
other rodent models of fatty liver associated hepatic insulin resistance 
[97, 00- 06].  
 
SLC 3A5 – therapeutic aspects 
 
Reducing INDY expression has been proven beneficial in terms 
of life span and/or metabolic regulation in all species tested so far. 
Therefore, it seems plausible to speculate that mINDY might be an 
interesting target for the treatment of metabolic disease, such as 
obesity, non-alcoholic fatty liver disease and type 2 diabetes 
[48, 07, 08]. To date, no specific therapeutic agents to modulate 
mINDY function or expression have been reported. Interestingly, 
human mINDY activity was described to be stimulated by Lithium, 
in concentrations that are observed during the treatment of bipolar 
disorders. Sun and colleagues reported on compounds, which inhibit 
the citrate transport protein (CTP) on the inner mitochondrial 
membrane [ 09, 0]. Moreover they could identify a compound with 
selectivity for mINDY over CTP [ ]. Whether or not such a 
compound will be amenable to therapeutic intervention remains to be 
determined. The high concentration needed to inhibit mINDY with 
this molecule makes it unlikely to become clinically relevant. The 
discovery of a more potent compound modulating mINDY function 
could provide a useful tool to delineate the structure and function of 
mINDY. Ultimately, a putative inhibitor of mINDY holds the 
potential to induce the beneficial effects of caloric restriction, without 
requiring severe caloric restriction in mammals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INDY and Metabolism 
5 
Volume No: 6, Issue: 7, e201303020 Computational and Structural Biotechnology Journal | www.csbj.org 
Acknowledgements
This work was supported by grants from the German Research
Foundation (DFG, Bl1292/4-1) and the Fritz-Thyssen-Foundation (Az
10.12.2.140).
Citation
Willmes DM, Birkenfeld AL (2013) The Role of INDY in
Metabolic Regulation. Computational and Structural Biotechnology
Journal. 6 (7): e201303020.
doi: http://dx.doi.org/1 0.5936/csbj.201303020
References
1. Anderson RM, Weindruch R (2012) The caloric restriction
paradigm: implications for healthy human aging. Am J Hum Bioi
24: 101-106.
2. Rogina B, Reenan RA, Nilsen SP, Helfand SL (2000) Extended
life-span conferred by cotransporter gene mutations in Drosophila.
Science 290: 2137-2140.
3. Birkenfeld AL, Lee HY, Guebre-Egziabher F, Alves TC, Jurczak
MJ, et al. (2011) Deletion of the mammalian INDY homolog
mimics aspects of dietary restriction and protects against adiposity
and insulin resistance in mice. Cell Metab 14: 184-195.
4. Markovich D (2008) Expression cloning and radiotracer uptakes in
Xenopus laevis oocytes. Nat Protoc 3: 1975-1980.
5. Markovich D (2001) Physiological roles and regulation of
mammalian sulfate transporters. Physiol Rev 81: 1499-1533.
6. Lee A, Beck L, Markovich D (2000) The human renal sodium
sulfate cotransporter (SLC13A1; hNaSi-1) cDNA and gene:
organization, chromosomal localization, and functional
characterization. Genomics 70: 354-363.
7. Beck L, Markovich D (2000) The mouse Na(+)-sulfate
cotransporter gene NasI. Cloning, tissue distribution, gene
structure, chromosomal assignment, and transcriptional regulation
by vitamin D. J Bioi Chem 275: 11880-11890.
8. Markovich D, Forgo J, Stange G, Biber J, Murer H (1993)
Expression cloning of rat renal Na+/S04(2-) cotransport. Proc
Nat! Acad Sci USA 90: 8073-8077.
9. Lotscher M, Custer M, Quabius ES, Kaissling B, Murer H, et al.
(1996) Immunolocalization of N alS04-cotransport (NaSi-1) in rat
kidney. Ptlugers Arch 432: 373-378.
10. Markovich D, Aronson PS (2007) Specificity and regulation of
renal sulfate transporters. Annu Rev Physiol69: 361-375.
11. Busch AE, Waldegger S, Herzer T, Biber J, Markovich D, et al.
(1994) Electrogenic cotransport of Na- and sulfate in Xenopus
oocytes expressing the cloned Na+S04(2-) transport protein NaSi-
1. J Bioi Chem 269: 12407-12409.
12. Dawson PA, Beck L, Markovich D (2003) Hyposulfatemia,
growth retardation, reduced fertility, and seizures in mice lacking a
functional NaSi-1 gene. Proc Nat! Acad Sci USA 100: 13704-
13709.
13. Dawson PA, Steane SE, Markovich D (2004) Behavioural
abnormalities of the hyposulphataemic Nas l knock-out mouse.
Behav Brain Res 154: 457-463.
14. Dawson PA, Steane SE, Markovich D (2005) Impaired memory
and olfactory performance in N aSi-1 sulphate transporter deficient
mice. Behav Brain Res 159: 15-20.
15. Dawson PA, Gardiner B, Grimmond S, Markovich D (2006)
Transcriptional profile reveals altered hepatic lipid and cholesterol
metabolism in hyposulfatemic NaSI null mice. Physiol Genomics
26: 116-124.
16. Dawson PA, Gardiner B, Lee S, Grimmond S, Markovich D
(2008) Kidney transcriptome reveals altered steroid homeostasis in
NaSI sulfate transporter null mice. J Steroid Biochem Mol Bioi
112: 55-62.
17. Dawson PA, Huxley S, Gardiner B, Tran T, McAuley JL, et al.
(2009) Reduced mucin sulfonation and impaired intestinal barrier
function in the hyposulfataemic NaSI null mouse. Gut 58: 910-
919.
18. Lee S, Kesby JP, Muslim MD, Steane SE, Eyles DW, et al. (2007)
Hyperserotonaemia and reduced brain serotonin levels in NaSI
sulphate transporter null mice. Neuroreport 18: 1981-1985.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INDY and Metabolism 
6 
Volume No: 6, Issue: 7, e201303020 Computational and Structural Biotechnology Journal | www.csbj.org 
19. Lee S, Dawson PA, Hewavitharana AK, Shaw PN, Markovich D
(2006) Disruption of NaSI sulfate transport function in mice leads
to enhanced acetaminophen-induced hepatotoxicity. Hepatology
43: 1241-1247.
20. Pajor AM, Sun N (1999) Protein kinase C-mediated regulation of
the renal Na(+)/dicarboxylate cotransporter, NaDC-l. Biochim
Biophys Acta 1420: 223-230.
21. Boehmer C, Embark HM, Bauer A, Palmada M, Yun CH, et al.
(2004) Stimulation of renal Na- dicarboxylate cotransporter 1 by
Na+/H+ exchanger regulating factor 2, serum and glucocorticoid
inducible kinase isoforms, and protein kinase B. Biochem Biophys
Res Commun 313: 998-1003.
22. Ho HT, Ko BC, Cheung AK, Lam AK, Tam S, et al. (2007)
Generation and characterization of sodium-dicarboxylate
cotransporter-deficient mice. Kidney Int 72: 63-71.
23. Bergeron MJ, Burzle M, Kovacs G, Simonin A, Hediger MA
(2011) Synthesis, maturation, and trafficking of human N a+-
dicarboxylate cotransporter NaDC1 requires the chaperone activity
of cyclophilin B. J BioI Chern 286: 11242-11253.
24. Meinild AK, Loo DD, Pajor AM, Zeuthen T, Wright EM (2000)
Water transport by the renal N a(+)-dicarboxylate cotransporter.
Am J Physiol Renal Physiol278: F777 -783.
25. Wang H, Fei YJ, Kekuda R, Yang-Feng TL, Devoe LD, et al.
(2000) Structure, function, and genomic organization of human
N a(+)-dependent high-affinity dicarboxylate transporter. Am J
Physiol Cell Physiol278: C1019-1030.
26. Markovich D, Murer H (2004) The SLC13 gene family of sodium
sulphate/carboxylate cotransporters. Pflugers Arch 447: 594-602.
27. Fujita T, Katsukawa H, Yodoya E, Wada M, Shimada A, et al.
(2005) Transport characteristics of N-acetyl-L-aspartate in rat
astrocytes: involvement of sodium-coupled high-affinity
carboxylate transporter NaC3/NaDC3-mediated transport system.
J Neurochem 93: 706-714.
28. Bai X, Chen X, Feng Z, Hou K, Zhang P, et al. (2006)
Identification of basolateral membrane targeting signal of human
sodium-dependent dicarboxylate transporter 3. J Cell Physiol 206:
821-830.
29. Yodoya E, Wada M, Shimada A, Katsukawa H, Okada N, et al.
(2006) Functional and molecular identification of sodium-coupled
dicarboxylate transporters in rat primary cultured cerebrocortical
astrocytes and neurons. J Neurochem 97: 162-173.
30. Wada M, Shimada A, Fujita T (2006) Functional characterization
of Na- -coupled citrate transporter NaC2/NaCT expressed in
primary cultures of neurons from mouse cerebral cortex. Brain Res
1081: 92-100.
31. Lamp J, Keyser B, Koeller DM, Ullrich K, Braulke T, et al. (2011)
Glutaric aciduria type 1 metabolites impair the succinate transport
from astrocytic to neuronal cells. J BioI Chern 286: 17777-17784.
32. Chen X, Tsukaguchi H, Chen XZ, Berger UV, Hediger MA
(1999) Molecular and functional analysis of SDCT2, a novel rat
sodium-dependent dicarboxylate transporter. J Clin Invest 103:
1159-1168.
33. Wang J, Chen X, Zhu H, Peng L, Hong Q (2003) Relationship
between aging and renal high-affinity sodium-dependent
dicarboxylate cotransporter-3 expression characterized with
antifusion protein antibody. J Gerontol A BioI Sci Med Sci 58:
B879-888.
34. Hagos Y, Burckhardt BC, Larsen A, Mathys C, Gronow T, et al.
(2004) Regulation of sodium-dicarboxylate cotransporter-3 from
winter flounder kidney by protein kinase C. Am J Physiol Renal
Physiol 286: F86-93.
35. Srisawang P, Chatsudthipong A, Chatsudthipong V (2007)
Modulation of succinate transport in Hep G2 cell line by PKC.
Biochim Biophys Acta 1768: 1378-1388.
36. Liu L, Zacchia M, Tian X, Wan L, Sakamoto A, et al. (2010) Acid
regulation of N aDC-1 requires a functional endothelin B receptor.
Kidney Int 78: 895-904.
37. Strungaru MH, Footz T, Liu Y, Berty FB, Belleau P, et al. (2011)
PITX2 is involved in stress response in cultured human trabecular
meshwork cells through regulation of SLC13A3. Invest
Ophthalmol Vis Sci 52: 7625-7633.
38. Sarvari M, Kallo I, Hrabovszky E, Solymosi N, Toth K, et al.
(2010) Estradiol replacement alters expression of genes related to
neurotransmission and immune surveillance in the frontal cortex of
middle-aged, ovariectomized rats. Endocrinology 151: 3847-3862.
39. Simino J, Shi G, Arnett D, Broeckel U, Hunt Sc, et al. (2011)
Variants on chromosome 6p22.3 associated with blood pressure in
the HyperGEN study: follow-up of FBPP quantitative trait loci.
Am J Hypertens 24: 1227-1233.
40. Bento JL, Palmer ND, Zhong M, Roh B, Lewis JP, et al. (2008)
Heterogeneity in gene loci associated with type 2 diabetes on
human chromosome 20q13.1. Genomics 92: 226-234.
41. Girard JP, Baekkevold ES, Feliu J, Brandtzaeg P, Amalric F (1999)
Molecular cloning and functional analysis of SUT-1, a sulfate
transporter from human high endothelial venules. Proc Nat! Acad
Sci USA 96: 12772-12777.
42. Markovich D, Regeer RR, Kunzelmann K, Dawson PA (2005)
Functional characterization and genomic organization of the
human Na(+)-sulfate cotransporter hNaS2 gene (SLC13A4).
Biochem Biophys Res Commun 326: 729-734.
43. Spencer AF, Lowenstein JM (1962) The supply of precursors for
the synthesis of fatty acids. J BioI Chem 237: 3640-3648.
44. Bloch K, Vance D (1977) Control mechanisms in the synthesis of
saturated fatty acids. Annu Rev Biochem 46: 263-298.
45. Ruderman NB, SahaAK, Vavvas D, Witters LA (1999) Malonyl-
CoA, fuel sensing, and insulin resistance. Am J Physiol 276: E1-
E18.
46. Inoue K, Zhuang L, Ganapathy V (2002) Human Na- -coupled
citrate transporter: primary structure, genomic organization, and
transport function. Biochem Biophys Res Commun 299: 465-471.
47. Gopal E, Miyauchi S, Martin PM, Ananth S, Srinivas SR, et al.
(2007) Expression and functional features of NaCT, a sodium-
coupled citrate transporter, in human and rat livers and cell lines.
Am J Physiol Gastrointest Liver PhysioI292: G402-408.
48. Mancusso R, Gregorio GG, Liu Q, Wang DN (2012) Structure
and mechanism of a bacterial sodium-dependent dicarboxylate
transporter. Nature 491: 622-626.
49. Knauf F, Mohebbi N, Teichert C, Herold D, Rogina B, et al.
(2006) The life-extending gene Indy encodes an exchanger for
Krebs-cycle intermediates. Biochem J 397: 25-29.
50. Knauf F, Rogina B, Jiang Z, Aronson PS, Helfand SL (2002)
Functional characterization and immunolocalization of the
transporter encoded by the life-extending gene Indy. Proc Nat!
Acad Sci USA 99: 14315-14319.
51. Inoue K, Zhuang L, Maddox DM, Smith SB, Ganapathy V (2002)
Structure, function, and expression pattern of a novel sodium-
coupled citrate transporter (NaCT) cloned from mammalian brain.
J BioI Chern 277: 39469-39476.
52. Inoue K, Fei YJ, Zhuang L, Gopal E, Miyauchi S, et al. (2004)
Functional features and genomic organization of mouse NaCT, a
sodium-coupled transporter for tricarboxylic acid cycle
intermediates. Biochem J 378: 949-957.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INDY and Metabolism 
7 
Volume No: 6, Issue: 7, e201303020 Computational and Structural Biotechnology Journal | www.csbj.org 
53. Fei YJ, Liu Jc, Inoue K, Zhuang L, Miyake K, et al. (2004)
Relevance of NAC-2, an Nai-coupled citrate transporter, to life
span, body size and fat content in Caenorhabditis elegans.
BiochemJ 379: 191-198.
54. Rogina B, Helfand SL (2013) Indy mutations and Drosophila
longevity. Front Genet 4: 47.
55. Wang PY, Neretti N, Whitaker R, Hosier S, Chang C, et al.
(2009) Long-lived Indy and calorie restriction interact to extend
life span. Proc Natl Acad Sci USA 106: 9262-9267.
56. Pajor AM (2006) Molecular properties of the SLC13 family of
dicarboxylate and sulfate transporters. Pflugers Arch 451: 597-605.
57. Brauburger K, Burckhardt G, Burckhardt BC (2011) The sodium-
dependent di- and tricarboxylate transporter, NaCT, is not
responsible for the uptake of D-, L-2-hydroxyglutarate and 3-
hydroxyglutarate into neurons. J Inherit Metab Dis 34: 477-482.
58. Inoue K, Zhuang L, Maddox DM, Smith SB, Ganapathy V (2003)
Human sodium-coupled citrate transporter, the orthologue of
Drosophila Indy, as a novel target for lithium action. Biochem J
374: 21-26.
59. Pijpe J, Pul N, van Duijn S, Brakefield PM, Zwaan BJ (2011)
Changed gene expression for candidate ageing genes in long-lived
Bicyclus anynana butterflies. Exp Gerontol 46: 426-434.
60. Martinez-Beamonte R, Navarro MA, Guillen N, Acin S, Arnal C,
et al. (2011) Postprandial rranscriptome associated with virgin
olive oil intake in rat liver. Front Biosci (Elite Ed) 3: 11-21.
61. Etcheverry A, Aubry M, de Tayrac M, Vauleon E, Boniface R, et
al. (2010) DNA methylation in glioblastoma: impact on gene
expression and clinical outcome. BMC Genomics 11: 701.
62. Neuschafer-Rube F, Lieske S, Kuna M, Henkel J, Perry RJ, et al.
(2013) The Mammalian INDY Homolog is Induced by CREB in
a Rat Model of Type 2 Diabetes. Diabetes.
63. Neuschafer-Rube F, Pathe-Neuschafer-Rube A, Hippenstiel S,
Kracht M, Puschel GP (2013) NF-kappaB-dependent IL-8
induction by prostaglandin E(2) receptors EP(1) and EP(4). Br J
Pharmacol168: 704-717.
64. Fegan J, Khan R, Poindexter J, Pak CY (1992) Gastrointestinal
citrate absorption in nephrolithiasis. J Uro1147: 1212-1214.
65. Pajor AM (2013) Sodium-coupled dicarboxylate and citrate
transporters from the SLC13 family. Pflugers Arch.
66. Rudman D, Dedonis JL, Fountain MT, Chandler JB, Gerron GG,
et al. (1980) Hypocitraturia in patients with gastrointestinal
malabsorption. N Engl J Med 303: 657-661.
67. Baruch SB, Burich RL, Eun CK, King VF (1975) Renal
metabolism of citrate. Med Clin North Am 59: 569-582.
68. Nieth H, Schollmeyer P (1966) Substrate-utilization of the human
kidney. Nature 209: 1244-1245.
69. Pashley DH, Cohen JJ (1973) Substrate interconversion in dog
kidney cortex slices: regulation by ECF-pH. Am J Physiol 225:
1519-1528.
70. Nielsen TT (1983) Plasma citrate in relation to glucose and free
fatty acid metabolism in man. Dan Med Bull 30: 357-378.
71. Dickens F (1941) The citric acid content of animal tissues, with
reference to its occurrence in bone and tumour. Biochem J 35:
1011-1023.
72. Liu S, Tang W, Fang J, Ren J, Li H, et al. (2009) Novel regulators
of Fgf23 expression and mineralization in Hyp bone. Mol
Endocrinol23: 1505-1518.
73. Lee SH, Davis EJ (1979) Carboxylation and decarboxylation
reactions. Anaplerotic flux and removal of citrate cycle
intermediates in skeletal muscle. J BioI Chern 254: 420-430.
74. Nielsen TT, Thomsen PE (1979) Leg and splanchnic
arteriovenous differences of plasma citrate in exercising man. J
Appl Physiol Respir Environ Exerc Physiol46: 120-127.
75. Nielsen TT, Henningsen P, Bagger JP, Thomsen PE, Eyjolfsson K
(1980) Myocardial citrate metabolism in control subjects and
patients with coronary artery disease. Scand J Clin Lab Invest 40:
575-580.
76. Nielsen TT, Sorensen NS (1981) Daily plasma citrate rhythms in
man during feeding and fasting. Scand J Clin Lab Invest 41: 281-
287.
77. Thomassen A, Nielsen TT, Bagger JP, Charles P, Lovgreen NA, et
al. (1981) Circadian plasma citrate rhythms in juvenile diabetics.
Acta Med Scand 210: 163-171.
78. Neretti N, Wang PY, Brodsky AS, Nyguyen HH, White KP, et al.
(2009) Long-lived Indy induces reduced mitochondrial reactive
oxygen species production and oxidative damage. Proc Natl Acad
Sci USA 106: 2277-2282.
79. Hursting SD, Lavigne JA, Berrigan D, Perkins SN, Barrett JC
(2003) Calorie restriction, aging, and cancer prevention:
mechanisms of action and applicability to humans. Annu Rev Med
54: 131-152.
80. Fontana L, Klein S (2007) Aging, adiposity, and calorie restriction.
JAMA 297: 986-994.
81. Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka
KJ, et al. (2009) Caloric restriction delays disease onset and
mortality in rhesus monkeys. Science 325: 201-204.
82. Lopez-Lluch G, Irusta PM, Navas P, de Cabo R (2008)
Mitochondrial biogenesis and healthy aging. Exp Gerontol 43:
813-819.
83. Mattison JA, Roth GS, Beasley TM, Tilmont EM, Handy AM, et
al. (2012) Impact of caloric restriction on health and survival in
rhesus monkeys from the NIA study. Nature 489: 318-321.
84. Fei YJ, Inoue K, Ganapathy V (2003) Structural and functional
characteristics of two sodium-coupled dicarboxylate transporters
(ceNaDC1 and ceNaDC2) from Caenorhabditis elegans and their
relevance to life span. J BioI Chern 278: 6136-6144.
85. Shulman GI, Helfand SL (2011) Indy knockdown in mice mimics
elements of dietary restriction. Aging (Albany NY) 3: 701.
86. Ruderman NB, Carling D, Prentki M, Cacicedo JM (2013)
AMPK, insulin resistance, and the metabolic syndrome. J Clin
Invest 123: 2764-2772.
87. Zhang BB, Zhou G, Li C (2009) AMPK: an emerging drug target
for diabetes and the metabolic syndrome. Cell Metab 9: 407-416.
88. Jordan SD, Kruger M, Willmes DM, Redemann N, Wunderlich
FT, et al. (2011) Obesity-induced overexpression of miRNA-143
inhibits insulin-stimulated AKT activation and impairs glucose
metabolism. Nat Cell BioI 13: 434-446.
89. Birkenfeld AL, Lee HY, Majumdar S, Jurczak MJ, Camporez JP, et
al. (2011) Influence of the hepatic eukaryotic initiation factor
2alpha (eIF2alpha) endoplasmic reticulum (ER) stress response
pathway on insulin-mediated ER stress and hepatic and peripheral
glucose metabolism. J BioI Chern 286: 36163-36170.
90. Bailly-Maitre B, Belgardt BF, Jordan SD, Coornaert B, von
Freyend MJ, et al. (2010) Hepatic Bax inhibitor-I inhibits
IRE1 alpha and protects from obesity-associated insulin resistance
and glucose intolerance. J BioI Chem 285: 6198-6207.
91. Loffler MG, Birkenfeld AL, Philbrick KM, Belman JP,
Habtemichael EN, et al. (2013) Enhanced fasting glucose turnover
in mice with disrupted action of TUG protein in skeletal muscle. J
BioI Chem 288: 20135-20150.
92. Kumashiro N, Beddow SA, Varner DF, Majumdar SK, Cantley JL,
et al. (2013) Targeting pyruvate carboxylase reduces
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: 
INDY, citrate, insulin resistance, diabetes, obesity, longevity 
 
Competing Interests:  
The authors have declared that no competing interests exist. 
 
 
 
© 2013 Willmes and Birkenfeld.  
Licensee: Computational and Structural Biotechnology Journal.   
This is an open-access article distributed under the terms of the Creative 
Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original 
author and source are properly cited. 
 
 
What is the advantage to you of publishing in Computational and 
Structural Biotechnology Journal (CSBJ) ? 
 
 Easy 5 step online submission system & online manuscript tracking 
 Fastest turnaround time with thorough peer review 
 Inclusion in scholarly databases 
 Low Article Processing Charges 
 Author Copyright 
 Open access, available to anyone in the world to download for free 
 
WWW.CSBJ.ORG 
 
INDY and Metabolism 
8 
Volume No: 6, Issue: 7, e201303020 Computational and Structural Biotechnology Journal | www.csbj.org 
gluconeogenesis and adiposity and improves insulin resistance.
Diabetes.
93. Shulman GI (2000) Cellular mechanisms of insulin resistance. J
Clin Invest 106: 171-176.
94. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, et al. (2004)
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver
disease. J Bioi Chern 279: 32345-32353.
95. Samuel VT, Petersen KF, Shulman GI (2010) Lipid-induced
insulin resistance: unravelling the mechanism. Lancet 375: 2267-
2277.
96. Samuel VT, Liu ZX, Wang A, Beddow SA, Geisler JG, et al.
(2007) Inhibition of protein kinase Cepsilon prevents hepatic
insulin resistance in nonalcoholic fatty liver disease. J Clin Invest
117: 739-745.
97. Erion DM, Shulman GI (2010) Diacylglycerol-mediated insulin
resistance. Nat Med 16: 400-402.
98. Birkenfeld AL, Shulman GI (2013) Non alcoholic fatty liver
disease, hepatic insulin resistance and type 2 diabetes.
Hepatology.epub ahead of print
99. Samuel VT, Shulman GI (2012) Mechanisms for insulin
resistance: common threads and missing links. Cell 148: 852-871.
100. Jornayvaz FR, Jurczak MJ, Lee HY, Birkenfeld AL, Frederick DW,
et al. (2010) A high-fat, ketogenic diet causes hepatic insulin
resistance in mice, despite increasing energy expenditure and
preventing weight gain. Am J Physiol Endocrinol Metab 299:
E808-815.
101. Lee HY, Choi CS, Birkenfeld AL, Alves TC, Jornayvaz FR, et al.
(2010) Targeted expression of catalase to mitochondria prevents
age-associated reductions in mitochondrial function and insulin
resistance. Cell Metab 12: 668-674.
102. Jurczak MJ, Lee HY, Birkenfeld AL, Jornayvaz FR, Frederick DW,
et al. (2011) SGLT2 deletion improves glucose homeostasis and
preserves pancreatic beta-cell function. Diabetes 60: 890-898.
103. Jornayvaz FR, Birkenfeld AL, Jurczak MJ, Kanda S, Guigni BA, et
al. (2011) Hepatic insulin resistance in mice with hepatic
overexpression of diacylglycerol acyltransferase 2. Proc Nat! Acad
Sci V S A 108: 5748-5752.
104. Lee HY, Birkenfeld AL, Jornayvaz FR, Jurczak MJ, Kanda S, et al.
(2011) Apolipoprotein cm overexpressing mice are predisposed to
diet- induced hepatic steatosis and hepatic insulin resistance.
Hepatology 54: 1650-1660.
105. Pajvani VB, Shawber C], Samuel VT, BirkenfeldAL, Shulman GI,
et al. (2011) Inhibition of Notch signaling ameliorates insulin
resistance in a Fox01-dependent manner. Nat Med 17: 961-967.
106. Jurczak MJ, Lee AH, Jornayvaz FR, Lee HY, Birkenfeld AL, et al.
(2012) Dissociation of inositol-requiring enzyme (IRE 1alpha)-
mediated c-jun N-terminal kinase activation from hepatic insulin
resistance in conditional X-box-binding protein-1 (XBP1) knock-
out mice. J Bioi Chern 287: 2558-2567.
107. Frankel S, Rogina B (2012) Indy mutants: live long and prosper.
Front Genet 3: 13.
108. Schindler C (2012) New therapeutic efforts and upcoming
developments in the field of diabetes medicine and endocrinology.
Ther Adv Endocrinol Metab 3: 51-53.
109. Aluvila S, Sun J, Harrison DH, Walters DE, Kaplan RS (2010)
Inhibitors of the mitochondrial citrate transport protein: validation
of the role of substrate binding residues and discovery of the first
purely competitive inhibitor. Mol Pharmacol 77: 26-34.
110. Irwin JJ, Shoichet BK (2005) ZINC--a free database of
commercially available compounds for virtual screening. J Chern
InfModel45: 177-182.
111. Sun J, Aluvila S, Kotaria R, Mayor JA, Walters DE, et al. (2010)
Mitochondrial and Plasma Membrane Citrate Transporters:
Discovery of Selective Inhibitors and Application to
Structure/Function Analysis. Mol Cell Pharmacol2: 101-110.
